Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy Versus Surgery Alone in Resectable Esophageal Squamous Cell Carcinoma

Trial Profile

Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy Versus Surgery Alone in Resectable Esophageal Squamous Cell Carcinoma

Suspended
Phase of Trial: Phase II/III

Latest Information Update: 10 Apr 2017

At a glance

  • Drugs Cisplatin (Primary) ; Nimotuzumab (Primary) ; Paclitaxel (Primary)
  • Indications Oesophageal cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Apr 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
    • 05 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2018.
    • 05 Apr 2017 Status changed from recruiting to suspended.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top